Long-term results of the prospective aortic dissection DRAGON study presented at CX2023
On April 27, 2023, the investigators, represented by Prof. Dr Victor Costache, presented at CX Symposium 2023 the “Long-term safety outcomes of patients with type B aortic dissection treated with multilayer stents: Results from a prospective multicenter pilot study” (https://www.cxsymposium.com).
In this study, initiated in 2016 and conducted in Europe, 24 patients with high-risk type B aortic dissection (TBAD) were treated with multilayer stents. The results, after a mean follow-up of 55 months (38-76 months) are promising with high survival rate (5-year survival estimated at 87.5%), no paraplegia, no stroke, no end-organ ischemia, no aortic-related reintervention, and no device deficiencies.
Put in perspective of the previously published cases and prospective registry reporting the use of the multilayer stent in aortic dissection, these results indicate that the multilayer stent could be a safe long-term treatment option for high-risk TBAD patients, showing high overall survival without reinterventions, and with preserved long-term end-organ perfusion.
To watch the on-demand version: https://www.cxsymposium.com